Stuart E Builder

45115028, Apr 16, 1985

Jun 1, 1984

6/615676

Stuart E. Builder - Belmont CA
John R. Ogez - San Mateo CA

Genentech, Inc. - South San Francisco CA

C07G 700

260112R

A process for purifying heterologous proteins from higher molecular weight components, including dissolving the heterologous protein in a strong denaturing solution and removing the higher molecular weight components using a molecular sieve or high speed centrifugation.

54516609, Sep 19, 1995

Dec 13, 1993

8/166337

Stuart E. Builder - Belmont CA
Charles V. Olson - Pacifica CA
David Reifsnyder - San Mateo CA

Genentech, Inc. - South San Francisco CA

A61K 3818
A61K 3830
C07K 122
C07K 14475

530344

A process is provided for selectively separating a polypeptide of interest from components of differing hydrophobicity in a mixture comprising the steps of: (a) passing the mixture through underivatized silica particles such that the polypeptide adheres to the silica particles; (b) washing the silica particles to remove impurities; and (c) eluting the polypeptide from the silica particles with a buffer comprising an alcoholic or polar aprotic solvent and an alkaline earth, an alkali metal, or an inorganic ammonium salt.

57233101, Mar 3, 1998

Feb 7, 1995

8/385187

Stuart Builder - Belmont CA
Roger Hart - Burlingame CA
Philip Lester - San Lorenzo CA
John Ogez - Redwood City CA
David Reifsnyder - San Mateo CA

Genentech, Inc. - South San Francisco CA

C07K 120
C07K 1465
C07K 1461
C12N 100

435 691

A method is described for isolating an exogenous polypeptide in a non-native conformation from cells, such as an aqueous fermentation broth, in which it is prepared comprising contacting the polypeptide with a chaotropic agent and preferably a reducing agent and with phase-forming species to form multiple aqueous phases, with one of the phases being enriched in the polypeptide and depleted in the biomass solids and nucleic acids originating from the cells. Preferably, the method results in two aqueous phases, with the upper phase being enriched in the polypeptide.

47770430, Oct 11, 1988

Dec 17, 1985

6/811081

William F. Bennett - San Francisco CA
Stuart E. Builder - Belmont CA
Larry A. Gatlin - Concord CA

Genentech, Inc. - South San Francisco CA

A61K 37547
A61K 31195

424 9464

Disclosed are novel, stable pharmaceutically acceptable compositions containing human tissue plasminogen activator, featuring, for example, an argininum ion containing buffer as a component. Also disclosed are associated means and methods for preparing and using such compositions in various forms.

57566720, May 26, 1998

Jun 6, 1995

8/470108

Stuart Builder - Belmont CA
Roger Hart - Burlingame CA
Philip Lester - San Lorenzo CA
David Reifsnyder - San Mateo CA

Genentech, Inc. - So. San Francisco CA

C07K 14475
A61K 3822

530350

A composition is provided comprising about 0. 1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0. 2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0. 1 to 9M of a chaotropic agent, and about 0. 01 to 15. mu. M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.

58080066, Sep 15, 1998

Oct 11, 1994

8/318628

Stuart Builder - Belmont CA
Roger Hart - Burlingame CA
Philip Lester - San Lorenzo CA
David Reifsnyder - San Mateo CA

Genentech, Inc. - S. San Francisco CA

C07K 14475
A61K 3822

530399

A composition is provided comprising about 0. 1 to 15 mg/ml of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0. 2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0. 1 to 9M of a chaotropic agent, and about 0. 01 to 15. mu. M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.

56633041, Sep 2, 1997

Aug 20, 1993

8/110664

Stuart Builder - Belmont CA
Roger Hart - Burlingame CA
Philip Lester - San Lorenzo CA
David Reifsnyder - San Mateo CA

Genentech, Inc. - San Francisco CA

C07K 14475
C12N 1518

530399

A composition is provided comprising about 0. 1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0. 2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0. 1 to 9M of a chaotropic agent, and about 0. 01 to 15. mu. M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.

46209484, Nov 4, 1986

Jun 1, 1984

6/615681

Stuart E. Builder - Belmont CA
John R. Ogez - San Mateo CA

Genentech, Inc. - South San Francisco CA

C08G 312

530419

A process for isolating and purifying refractile proteins from host cell culture including treating the host cell culture with a buffered solution to solubilize host protein, leaving refractile protein insoluble, treating the insoluble fraction with a strongly denaturing solution containing a reducing agent to solubilize the refractile protein, and renaturing the refractile protein.